Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2017

View Archived Issues

Australian grant supports neuroblastoma research

Can-Fite Biopharma set to begin phase III ACRobat study of piclidenoson

PTC Therapeutics announces annual STRIVE grant award program for Duchenne muscular dystrophy

Novel nucleoside-modified mRNA vaccine elicits rapid and durable protective immunity against ZIKV

BioRestorative Therapies receives FDA clearance to initiate phase II trial of BRTX-100

Mitsubishi Tanabe Pharma updates pipeline progress of third quarter of fiscal 2016

FibroGen presents promising phase I results for FG-3019 in patients with pancreatic cancer

COMPASS trial of Xarelto stopped early for efficacy

First rabbit para-renal cancer model generated using VX2 tumors

AbbVie initiates phase I study of ABBV-951 for Parkinson's disease

Novo Nordisk presents highlights of fourth quarter 2016

FDA advisory committee meeting not needed for Portola Pharmaceuticals' betrixaban NDA

hVIVO reports data from two phase IIa studies of PrEP Biopharm's PrEP-001

Epinomics collaborates with Parker Institute for Cancer Immunotherapy

Spotlight Innovation hires CRO for further preclinical testing of candidate for SMA

Merck & Co. describes novel adenosine A2A receptor antagonists

Jazz initiates phase II study of JZP-110 to treat excessive sleepiness in Parkinson's disease

Altered immunity-related gene expression in adolescents with chronic fatigue syndrome

MeiraGTx gives update on its clinical trials in achromatopsia and Leber congenital amaurosis

Oncoceutics' ONC-201 granted U.S. orphan drug status for mantle cell lymphoma

Anti-HER2 bispecific antibody ZW-25 receives FDA orphan designation for gastric cancer

Acorda Therapeutics reports phase III data on CVT-301 in Parkinson's disease

Chrysalis Biotherapeutics begins contract with NIAID for TP-508 as nuclear countermeasure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...